Skip to content

Study · Measured the body's own peptide · 1994

2 results

Vasoactive intestinal polypeptide (VIP) secretion and refractory diarrhea in patients with AIDS or AIDS-related complex (ARC).

Manfredi R, Vezzadini P, Fanti MP, Chiodo F

Scandinavian journal of infectious diseases1 Jan 1994Cited by 8 (Europe PMC)

PMID8191241 (opens in a new tab)DOI10.3109/00365549409008591 (opens in a new tab)PepBankPUB-08191241
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    Elevated plasma levels of the body's own VIP were found in 7 of 11 patients with AIDS or AIDS-related complex who had prolonged intractable diarrhea.

    In plain wordsIn people with AIDS or ARC and long-lasting diarrhea, the body's own VIP was raised in the blood in 7 of 11.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreasePlasma VIP level in AIDS or ARC patients with refractory diarrhea
    Study

    n = 11

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Measurements

    Patients with elevated plasma VIP
    7 patients
    of 11 with AIDS or ARC

    Source sentences

    Summary
    Elevated plasma levels of vasoactive intestinal polypeptide (VIP) (as assessed by a radio-immunoassay), were found in 7/11 patients with AIDS or AIDS-related Complex (ARC), evaluated because of prolonged intractable diarrhea with either an infectious (6 cases) or a non-infectious (5 cases) etiology.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In six patients with AIDS or ARC and refractory diarrhea, treatment with octreotide significantly reduced plasma levels of the body's own VIP.

    In plain wordsIn people with AIDS or ARC and diarrhea, octreotide treatment lowered the body's own VIP in the blood.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreasePlasma VIP after octreotide treatment
    Study

    n = 6

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Six subjects have been treated with the somatostatin analogue octreotide, which gave both a favourable clinical response and a significant reduction in plasma VIP concentrations.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.